Summary
Generics in Turkey industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Turkish generics market had total revenues of $2.0bn in 2018, representing a compound annual growth rate (CAGR) of 21.2% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 1.6% between 2014 and 2018, to reach 59.4% of total pharma volume.
- Despite being launched in 2003, the Health Transformation Program was intended to improve hospital infrastructure and utilize the latest technology. However, in late 2014, the first PPP project financially closed after an investment from Siemens.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Turkey
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Turkey
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Turkey generics market with five year forecasts by both value and volume
Reasons to buy
- What was the size of the Turkey generics market by value in 2018?
- What will be the size of the Turkey generics market in 2023?
- What factors are affecting the strength of competition in the Turkey generics market?
- How has the market performed over the last five years?
- How large is Turkey’s generics market in relation to its regional counterparts?
'
Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. Which players have been most successful in the recent past (1-3 years)?
7.3. What mergers or acquisitions have taken place in the last year?
8 Company Profiles
8.1. Deva Holding AS
8.2. Pfizer Inc.
8.3. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
8.4. Nobelpharma Co Ltd
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: Turkey generics market value: $ million, 2014-18
Table 2: Turkey generics market volume: % of total pharma, 2014-18
Table 3: Turkey generics market geography segmentation: $ million, 2018
Table 4: Turkey generics market value forecast: $ million, 2018-23
Table 5: Turkey generics market volume forecast: % of total pharma, 2018-23
Table 6: Deva Holding AS: key facts
Table 7: Deva Holding AS: Annual Financial Ratios
Table 8: Deva Holding AS: Key Employees
Table 9: Pfizer Inc.: key facts
Table 10: Pfizer Inc.: Annual Financial Ratios
Table 11: Pfizer Inc.: Key Employees
Table 12: Pfizer Inc.: Key Employees Continued
Table 13: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: key facts
Table 14: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: Key Employees
Table 15: Nobelpharma Co Ltd: key facts
Table 16: Nobelpharma Co Ltd: Key Employees
Table 17: Nobelpharma Co Ltd: Key Employees Continued
Table 18: Turkey size of population (million), 2014-18
Table 19: Turkey gdp (constant 2005 prices, $ billion), 2014-18
Table 20: Turkey gdp (current prices, $ billion), 2014-18
Table 21: Turkey inflation, 2014-18
Table 22: Turkey consumer price index (absolute), 2014-18
Table 23: Turkey exchange rate, 2014-18
List of Figures
Figure 1: Turkey generics market value: $ million, 2014-18
Figure 2: Turkey generics market volume: % of total pharma, 2014-18
Figure 3: Turkey generics market geography segmentation: % share, by value, 2018
Figure 4: Turkey generics market value forecast: $ million, 2018-23
Figure 5: Turkey generics market volume forecast: % of total pharma, 2018-23
Figure 6: Forces driving competition in the generics market in Turkey, 2018
Figure 7: Drivers of buyer power in the generics market in Turkey, 2018
Figure 8: Drivers of supplier power in the generics market in Turkey, 2018
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Turkey, 2018
Figure 10: Factors influencing the threat of substitutes in the generics market in Turkey, 2018
Figure 11: Drivers of degree of rivalry in the generics market in Turkey, 2018
